{
  "docId": "019de076-928b-754c-8bda-49c7fed3154d",
  "docSlug": "58a8f830d3c9f9a6fedd64a0d2a10227",
  "documentTitle": "ATAI | Investor Presentation Deck | 34 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 34,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-928b-754c-8bda-49c7fed3154d/29",
  "deckHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d",
  "deckJsonHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d.json",
  "deckAnchorHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Trial status: First patient dosed in 1Q'23, Topline data anticipated mid'25",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a12341c-ef90-49f8-95e1-54d4d63981a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.08,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Randomization flow diagram showing 1:1:1 split into three arms: RL-007 40mg, RL-007 20mg, and Placebo over a timeline from Day 1 to Week 6.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87b6fe01-f440-4382-b367-6f8a8a099d1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.58,
        "y": 0.38
      },
      "kind": "list",
      "text": "Primary Endpoint: MCCB neurocognitive composite score at Week 6. Key Secondary Endpoints: Select Individual Components of MCCB, including BACS Symbol Coding; Clinical Global Impression Score.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0234ee68-d560-4080-b80c-ee74aaa21745",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Randomized, placebo-controlled study of RL-007 in ~234 patients with CIAS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aff7af40-bcf4-4cf4-bba3-fe111d42af24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: MCCB = MATRICS Consensus Cognitive Battery; BACS = Brief Assessment of Cognition in Schizophrenia; CIAS = Cognitive Impairment Associated with Schizophrenia; TID = 3x/day dosing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cde4ec4-1ce4-4241-a2dc-33596227429b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Clinical Trial Design: RL-007 Phase 2b Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81707314-cdda-4ffa-94fb-50eb4a190b66",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "f1c7d283-c62f-4eda-97a2-7476b74fbf15",
      "evidence": "The slide's structure, which includes a clear problem statement ( Situation), a description of the clinical trial design (Context), a question (Question), and an answer (Answer), aligns with the SCQA framework.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c65cfc1b-596e-44b3-abf6-776a6539dcbf",
      "evidence": "The deck emphasizes the need for effective treatments",
      "position": 0,
      "objective": "Highlight the importance of addressing mental health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7657d45c-02c7-40ab-9afc-a644dc2ed2c5",
      "evidence": "The deck follows a structure that aligns with the Golden Circle",
      "position": 1,
      "objective": "Explain the company's approach and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}